<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Illumina Inc — News on 6ix</title>
<link>https://6ix.com/company/illumina-inc</link>
<description>Latest news and press releases for Illumina Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 13:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/illumina-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835835478dffbe2df0fca4b.webp</url>
<title>Illumina Inc</title>
<link>https://6ix.com/company/illumina-inc</link>
</image>
<item>
<title>DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows</title>
<link>https://6ix.com/company/illumina-inc/news/dragen-v45-supports-illuminas-new-trupath-genome-and-5-base-assays-drives-insights-across-germline-oncology-and-multiomic-workflows</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/dragen-v45-supports-illuminas-new-trupath-genome-and-5-base-assays-drives-insights-across-germline-oncology-and-multiomic-workflows</guid>
<pubDate>Thu, 16 Apr 2026 13:15:00 GMT</pubDate>
<description>Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.5 software (v4.5), one of the most substantial expansions of the software's capabilities to date. As genomic researchers contend with complex regions of the genome, degraded samples, and multiomic data types, DRAGEN v4.5 delivers new ways to reduce noise, improve accuracy, and extract biological signals, giving researchers greater discovery power to fuel findings in rare disease and oncology.</description>
</item>
<item>
<title>Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-bring-genomic-data-and-scalable-software-to-the-fight-against-pediatric-cancer-and-rare-disease</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-bring-genomic-data-and-scalable-software-to-the-fight-against-pediatric-cancer-and-rare-disease</guid>
<pubDate>Tue, 14 Apr 2026 13:15:00 GMT</pubDate>
<description>Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care.</description>
</item>
<item>
<title>Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-to-announce-first-quarter-2026-financial-results-on-thursday-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-to-announce-first-quarter-2026-financial-results-on-thursday-april-30-2026</guid>
<pubDate>Thu, 09 Apr 2026 20:30:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026.</description>
</item>
<item>
<title>Illumina Announces Changes to Board of Directors</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-announces-changes-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-announces-changes-to-board-of-directors</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>David P. King nominated to support next phase of growth and innovation;Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the BoardSAN</description>
</item>
<item>
<title>Illumina and Labcorp expand collaboration to broaden access to precision oncology testing</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory</description>
</item>
<item>
<title>Illumina advances preventive genomics through strategic consortium with Veritas Genetics</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-advances-preventive-genomics-through-strategic-consortium-with-veritas-genetics</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-advances-preventive-genomics-through-strategic-consortium-with-veritas-genetics</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven</description>
</item>
<item>
<title>GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor</title>
<link>https://6ix.com/company/illumina-inc/news/grail-announces-retirement-of-ceo-bob-ragusa-and-appointment-of-josh-ofman-md-mshs-as-successor-69</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/grail-announces-retirement-of-ceo-bob-ragusa-and-appointment-of-josh-ofman-md-mshs-as-successor-69</guid>
<pubDate>Thu, 12 Mar 2026 20:30:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a</description>
</item>
<item>
<title>Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering</title>
<link>https://6ix.com/company/illumina-inc/news/alliance-for-genomic-discovery-expands-with-regeneron-genetics-center-membership-and-new-proteomics-data-offering-6</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/alliance-for-genomic-discovery-expands-with-regeneron-genetics-center-membership-and-new-proteomics-data-offering-6</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Dataset grows to more than 312,000 whole genomes with longitudinal clinical dataGSK is one of the first to lead a further expansion of 50,000 whole genomes</description>
</item>
<item>
<title>Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-whole-genome-sequencing-technology-to-accelerate-rare-disease-testing-in-florida</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-whole-genome-sequencing-technology-to-accelerate-rare-disease-testing-in-florida</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American childrenSAN DIEGO, Feb.</description>
</item>
<item>
<title>Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-launches-trupath-genome-unveils-novaseq-x-roadmap-and-drives-cancer-breakthroughs-with-connected-multiomics</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-launches-trupath-genome-unveils-novaseq-x-roadmap-and-drives-cancer-breakthroughs-with-connected-multiomics</guid>
<pubDate>Thu, 26 Feb 2026 23:59:00 GMT</pubDate>
<description>Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a suite of powerful advancements that will significantly accelerate the next era of genomic discovery. Unveiled at the Advances in Genome Biology and Technology (AGBT) 2026 conference, the announcements include the launch of TruPath™ Genome, a new standard in genomic insight; a groundbreaking roadmap for the NovaSeq X Series; and new partner-driven cancer breakthroughs powered by Illumin</description>
</item>
<item>
<title>Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-partners-go-beyond-the-genome-driving-cancer-breakthroughs-using-spatial-transcriptomics-epigenomics-and-proteomics</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-partners-go-beyond-the-genome-driving-cancer-breakthroughs-using-spatial-transcriptomics-epigenomics-and-proteomics</guid>
<pubDate>Wed, 25 Feb 2026 14:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to combine more than one omic insight reveals unprecedented biological depth and knowledge, all of which is streamlined by Illumina Connected Multiomics for multimodal data analysis. The combined portfolio delivers new insights for precision diagnostics, targeted therapeutics development, and understanding</description>
</item>
<item>
<title>Illumina launches TruPath Genome, setting a new standard in genomic insight</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-launches-trupath-genome-setting-a-new-standard-in-genomic-insight</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-launches-trupath-genome-setting-a-new-standard-in-genomic-insight</guid>
<pubDate>Tue, 24 Feb 2026 17:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.</description>
</item>
<item>
<title>Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-unveils-roadmap-of-groundbreaking-novaseq-x-advancements-in-data-quality-output-speed-and-flexibility</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-unveils-roadmap-of-groundbreaking-novaseq-x-advancements-in-data-quality-output-speed-and-flexibility</guid>
<pubDate>Mon, 23 Feb 2026 14:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 billion reads (35B). Staggered starts and new flow cells go live across the customer base in the coming weeks.</description>
</item>
<item>
<title>GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/illumina-inc/news/grail-reports-fourth-quarter-and-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/grail-reports-fourth-quarter-and-full-year-2025-financial-results-1</guid>
<pubDate>Thu, 19 Feb 2026 21:02:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 and provided business updates.</description>
</item>
<item>
<title>Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-reports-financial-results-fourth-210500529</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-reports-financial-results-fourth-210500529</guid>
<pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
<description>Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the fourth quarter and fiscal year 2025.</description>
</item>
<item>
<title>Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-san-diego-zoo-wildlife-141500614</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-san-diego-zoo-wildlife-141500614</guid>
<pubDate>Tue, 03 Feb 2026 14:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom. Illumina will sequence up to 4,000 samples representing 1,300 species in the Frozen Zoo®. Genomic insights will be applied to real-world conservation challenges and efforts to safeguard animal species wor</description>
</item>
<item>
<title>PacBio Completes Sale of Short-Read Sequencing Assets</title>
<link>https://6ix.com/company/illumina-inc/news/pacbio-completes-sale-of-short-read-sequencing-assets</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/pacbio-completes-sale-of-short-read-sequencing-assets</guid>
<pubDate>Mon, 02 Feb 2026 14:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Ill</description>
</item>
<item>
<title>Illumina completes acquisition of SomaLogic</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-completes-acquisition-somalogic-140500440</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-completes-acquisition-somalogic-140500440</guid>
<pubDate>Fri, 30 Jan 2026 14:05:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.</description>
</item>
<item>
<title>Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-secures-cms-reimbursement-trusight-141500707</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-secures-cms-reimbursement-trusight-141500707</guid>
<pubDate>Tue, 20 Jan 2026 14:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care.</description>
</item>
<item>
<title>Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery</title>
<link>https://6ix.com/company/illumina-inc/news/illumina-introduces-billion-cell-atlas-141500418</link>
<guid isPermaLink="true">https://6ix.com/company/illumina-inc/news/illumina-introduces-billion-cell-atlas-141500418</guid>
<pubDate>Tue, 13 Jan 2026 14:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.</description>
</item>
</channel>
</rss>